Biosnese Webster’s Optrell mapping catheter launches in USA

Optrell mapping catheter

Biosense Webster has today announced the US launch of the Optrell mapping catheter with Trueref technology powered by the Carto 3 system.

The Optrell mapping catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AF), redo AF ablation, atrial tachycardia, and ventricular tachycardia.

The new catheter includes 48 electrodes symmetrically distributed across and along six splines and combines with the Carto 3 system to deliver insights and high-resolution directional mapping. Additionally, the Optrell mapping catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart. With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy.

“The Optrell mapping catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets,” said Pasquale Santangeli (Cleveland Clinic Main Campus, Cleveland, USA). “This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AF, redo AF ablation, atrial tachycardia, and ventricular tachycardia.”

The Optrell mapping catheter is powered by the Carto 3 system, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart.

“The Optrell mapping catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our Carto 3 mapping system, to diagnose and treat arrhythmias,” said Jasmina Brooks, president, Biosense Webster. “This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients.”

The Optrell mapping catheter with Trueref technology received US Food and Drug Administration (FDA) 510(k) clearance in 2022 and is now available in the U.S.

The Optrell mapping catheter with Trueref technology will be commercially available in Japan later this year.


Please enter your comment!
Please enter your name here